NBIX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 1202 min ago

@ $137.25

Išleistas: 28 birž. 2024 @ 21:37

Grąža: 0.31%

Ankstesnis signalas: birž. 28 - 16:31

Ankstesnis signalas: Pardavimas

Grąža: 1.02 %

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.08% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	1.41M
Vidutinė apimtis	789 275
Rinkos kapitalizacija	13.85B
EPS	$0.430 ( Q1 \| 2024-05-01 )
Kita pelno data	( $1.040 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	37.41 (Sector) 42.63 (Industry) 0
ATR14	$4.39 (3.19%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-05-31	Delaet Ingrid	Buy	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Non-Qualified Stock Option
2024-05-29	Sherwin Stephen A	Buy	25 000	Common Stock
2024-05-29	Sherwin Stephen A	Buy	15 000	Common Stock

INSIDER POWER
-31.10
Last 100 transactions
Buy: 277 011 \| Sell: 532 232

Koreliacija (AI algo v.1.1b): Overvalued: -0.08% $137.67 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.52 (weak negative)

Trumpas: -0.94 (very strong negative)

Signal:(54) Neutral

Neurocrine Biosciences Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Neurocrine Biosciences Koreliacija - Valiuta/Žaliavos

0.54
( weak )

-0.15
( neutral )

0.00
( neutral )

0.03
( neutral )

0.36
( neutral )

-0.24
( neutral )

Neurocrine Biosciences Finansinės ataskaitos

Annual	2023
Pajamos:	$1.89B
Bruto pelnas:	$1.85B (97.90 %)
EPS:	$2.56

FY	2023
Pajamos:	$1.89B
Bruto pelnas:	$1.85B (97.90 %)
EPS:	$2.56

FY	2022
Pajamos:	$1.49B
Bruto pelnas:	$1.47B (98.44 %)
EPS:	$1.610

FY	2021
Pajamos:	$1.13B
Bruto pelnas:	$1.12B (98.74 %)
EPS:	$0.940

Financial Reports:

No articles found.

Neurocrine Biosciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.